article 3 months old

API An Opportunity Few Have Identified?

Australia | May 02 2006

By Chris Shaw (Tokyo)

When a company fails to meet earnings expectations it suffers not only from a weaker share price but also from a loss of management credibility, which turns investors away.

The converse can also be true, as a new management team can spark improved performance through the introduction of new skills and strategies. Intersuisse suggests this is the situation at Australian Pharmaceutical industries (API), which it rates as Buy.

Management has received an infusion of new blood this year following the addition of new stores to its retail chain while the addition of Daniel Lucas as CEO adds to its credibility, leading the broker to suggest the stock represents a turnaround story following several years of relatively poor performance.

One advantage the company now has in the broker’s view is the focus on manufacturing. At the same time as Mayne Pharma (MYP) management was distracted with its recent de-merger, it has strengthened its position in the pharmaceutical wholesaling market.

Additionally, the broker is of the view the Priceline retail chain should be able to provide a boost to earnings, particularly as this year it will contribute for the full period.

Last year’s disappointing result also featured high administration and head office costs, meaning a 16% increase in sales from continuing operations was not enough to lift earnings, a situation where Intersuisse expects improvement this year.

The broker forecasts the stock will generate EPS this year of 15.8c and next year of 19.9c, which compares to 14.6c in 2005. Another attraction is the yield, which it estimates will increase from a fully franked 5.2% currently to closer to 6%.

Opinions in the FN Arena database suggest the positives identified by Intersuisse have yet to be picked up on by the broader market, as there remains one Underperform rating and two Hold recommendations on the stock. Aspect Huntley shares the view of Intersuisse (note: Intersuisse buys in Aspect Huntley research to add to its own inhouse research) while Macquarie too rates the stock positively. It should be noted though Macquarie’s Outperform was originally based on the potential total return for 2006 and was accompanied by a reduction in earnings estimates following what was viewed as a poor quality result in December.

The last closing price for API was $2.50, which compares to a range over the past year of $2.20-$3.45. The average target price currently stands at $2.91.

To share this story on social media platforms, click on the symbols below.

Click to view our Glossary of Financial Terms

Australian investors stay informed with FNArena – your trusted source for Australian financial news. We deliver expert analysis, daily updates on the ASX and commodity markets, and deep insights into companies on the ASX200 and ASX300, and beyond. Whether you're seeking a reliable financial newsletter or comprehensive finance news and detailed insights, FNArena offers unmatched coverage of the stock market news that matters. As a leading financial online newspaper, we help you stay ahead in the fast-moving world of Australian finance news.